

17th July, 2026

To,

**The Corporate Relationship Department
BSE Limited**
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.
Scrip Code: 539523

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.
Scrip Symbol: ALKEM

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)-
Updates on Acquisition.**

Dear Sir(s)/ Madam,

This is in continuation of our earlier intimations dated 13th February, 2026, 06th March, 2026 and 29th June 2026, wherein the Stock Exchanges were informed that M/s. Alkem Medtech Private Limited, a wholly owned subsidiary of the Company in India (“Alkem Medtech”), intends to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG (“Occlutech”), a company incorporated in Switzerland.

In this regard, we wish to inform you that, the said acquisition stands completed pursuant to the Share Purchase Agreement and accordingly, Occlutech will now be a step-down subsidiary of the Company.

A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a